Gastroenterology

FDA grants priority review to ripretinib for advanced gastrointestinal stromal tumors




The FDA granted priority review to ripretinib for treatment of advanced gastrointestinal stromal tumors, according to a press release from the agent’s manufacturer.
Ripretinib (Deciphera Pharmaceuticals) is a tyrosine kinase switch control inhibitor engineered to broadly inhibit KIT and platelet-derived growth factor receptor alpha-mutated kinases.
The FDA previously granted fast track and breakthrough therapy designations to the agent for use by patients with previously treated advanced gastrointestinal stromal tumors (GIST).
The agency is expected to make a decision on the new drug

Source link





Related posts

FDA approves ConvertX Biliary Stent System for bile duct obstructions

Newsemia

A Crohn’s and Colitis Disease Patient Story: Meet Erin Bush

Newsemia

Should you pop a hemorrhoid?

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy